Patents by Inventor Ralf SCHIRRMACHER

Ralf SCHIRRMACHER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fluorinated beta-hydroxybutyric acids for PET imaging
    Patent number: 11833228
    Abstract: Beta-hydroxybutyric acid-based radiopharmaceuticals, pharmaceutical compositions comprising same, methods for preparing same, and methods of using same for diagnostic imaging and non-imaging tracer studies are provided.
    Type: Grant
    Filed: August 13, 2020
    Date of Patent: December 5, 2023
    Assignee: The Governors Of The University Of Alberta
    Inventors: Stephanie Mattingly, Frank Wuest, Ralf Schirrmacher, Melinda Wuest, Eugene Fine
  • FLUORINATED BETA-HYDROXYBUTYRIC ACIDS FOR PET IMAGING
    Publication number: 20210046196
    Abstract: Beta-hydroxybutyric acid-based radiopharmaceuticals, pharmaceutical compositions comprising same, methods for preparing same, and methods of using same for diagnostic imaging and non-imaging tracer studies are provided.
    Type: Application
    Filed: August 13, 2020
    Publication date: February 18, 2021
    Applicant: The Governors of the University of Alberta
    Inventors: Stephanie MATTINGLY, Frank WUEST, Ralf SCHIRRMACHER, Melinda WUEST, Eugene FINE
  • MALEIMIDE-FUNCTIONALIZED GOLD NANOPARTICLES
    Publication number: 20140186263
    Abstract: A maleimide-functionalized gold nanoparticle is described herein. More specifically, a maleimide-functionalized gold nanoparticle of formula (I): is described, wherein “n” and “m” are integers independently ranging from 1 to 100.
    Type: Application
    Filed: May 31, 2012
    Publication date: July 3, 2014
    Applicant: THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY
    Inventors: Ralf Schirrmacher, Jun Zhu, R. Bruce Lennox
  • METHOD FOR TREATING DIABETES
    Publication number: 20120087919
    Abstract: Fusion proteins binding specifically to cell types of the islets of Langerhans and delivering therapeutic or prophylactic agents are provided herein, as well as compositions thereof. Methods for treating or preventing diseases related to the pancreas such as diabetes are also disclosed. The therapeutic or prophylactic agents include Nemo-binding domain peptides and other inhibitors of NF-kB activation.
    Type: Application
    Filed: September 1, 2011
    Publication date: April 12, 2012
    Applicant: THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/McGILL UNIVERSITY
    Inventors: Stephan SCHNEIDER, Ralf SCHIRRMACHER